A phase 3 cluster Randomized Control Trial was done in an area of intense resistance and malaria transmission in Ivory Coast between 2017 and 2019. All 40 villages received LLINs, and 3069 houses in 20 intervention villages received In2Care EaveTubes and window screening. This resulted in a median coverage of 73% (range 32 – 100%).

Results showed a significant impact on malaria transmission:

  • The In2Care EaveTube intervention reduced malaria case incidence with 38% on top of bednets.
  • Malaria case prevalence was reduced with 44%, and anaemia in young children with 30%.
  • Community protection gave 28% less malaria risk for people in untreated homes at ≥60% EaveTube coverage.
  • Intervention houses were not fully mosquito-proof (doors were left open): but did show 61% reduction in indoor anopheline densities. 
  • In2Care® EaveTubes reduced outdoor vector densities with 39% and lowered the EIR with 69%.
  • Social studies showed >90% of inhabitants liking the effects and wanting to keep using In2Care EaveTubes.

 

As product developer and IP owner, In2Care is preparing mass-scale Eave Tube manufacturing processes and developing sustainable business models for Eave Tube commercialization. Within the BMGF-funded project we are assessing different routes to market via Implementation pilots, for instance by implementing EaveTubes in a Sugar estate accommodations in North-Western Tanzania.

UA-22190788-1